Business News Network

Leading vaccine company born from Profectus Biotech and Medisun Medical Group new joint venture

May
18

The famous American vaccine company Profectus settled in Hong Kong

First recommend HPV cervical cancer treatment vaccine

BALTIMORE, MARYLAND, USA and HONG KONG, April 20, 2018

Profectus Biotech and Medisun Medical Group today announced the opening of a new joint venture in Hong Kong. The primary mission of the new company, ProMed BioSciences, Ltd., is to establish a leading vaccine company focused on the development of preventive and therapeutic vaccines for infectious diseases and cancer. The joint venture will leverage Profectus’ vaccine development expertise, clinically proven vaccine platform technology and a developing vaccine product line, in line with Medisun’s expertise, established clinical network and market access capabilities, expected in the second half of 2018 to put into operation.

The company’s first product development program will focus on the development, production and commercial application of prophylactic and therapeutic vaccines for HPV (human papillomavirus)-related lesions and cervical cancer [based on PBSVax® technology developed by Profectus]. ProMed BioSciences also plans to develop and treat hepatitis C virus (HCV), hepatitis B virus (HBV), herpes simplex virus (HSV), respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV). Chikungunya and Zika, as well as personalized vaccines to treat cancer. The joint venture is expected to launch new vaccines in their respective markets, which will help promote the development of new vaccines, but ultimately the goal is to benefit patients around the world.

Mr. Jeffery Meshulam (first from left), President of Profectus Biotechnology, Mr. Terry Lierman (second from left), Chairman of Medivh Medical Group, and Mr. Danny Wong (fourth from right), founder and executive chairman of Medisun Medical Group, at Profectus ,USA.

– Long-term strategic cooperation to address the huge demand for prevention and treatment of infectious diseases and cancer in Asia

-Profectus’ expertise in vaccine development and platform technology, combined with Medisun’s localized expertise and experience, to establish a leading Hong Kong vaccine company focused on serving Asia

“This strategic cooperation will help establish Profectus’ business in Hong Kong and China. Through close cooperation with Medisun, we can assist Hong Kong and China to develop advanced vaccine technology to help prevent and treat Asian patients. Mr. Jeffrey Meshulam, President of Profectus, said, “We are pleased to be able to work with recognized local partners to achieve the highest standards of scientific research and development integration and medical services.”

“This collaboration will help Profectus and Medisun to jointly produce life-saving vaccines for infectious diseases and cancer, and address the huge medical needs that have not been met in Hong Kong, China and Asia.” Mr. Danny Wong, founder and executive chairman of Medisun Medical Group, said “ProMed BioSciences will leverage Profectus’ expertise in vaccine development and technology, combined with Medisun’s local expertise and close links with healthcare facilities in Hong Kong and China, and government medical regulatory agencies to develop vaccines to provide leadership for Asian patients disease prevention and treatment programs.”

ProMed BioSciences will focus on the following:

• Conduct technical research in Hong Kong or China

• Conduct clinical trials in Hong Kong or China

• Promote the expansion of Medisun Medical Center

• Develop vaccines to address disease prevention needs

• leverage to maximize the expertise of both partners

Mr. Jeffery Meshulam, President of Profectus Biotechnology (first from left), Mr. Terry Lierman, Chairman of Medisun Medical Group (first from right), Mr. Danny Wong, founder and executive chairman of Medisun Medical Group (middle), at the US headquarters of  Profectus.

About ProMed BioSciences

ProMed BioSciences Limited is a joint venture between Profectus BioSciences (USA) and Medisun Medical Group (Hong Kong) in Hong Kong to develop and conduct new vaccine clinical trials and commercial applications to address infectious diseases and cancer in Asia with the huge demand for prevention and treatment.

About Medisun

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as quality hospitals and treatment centers. Medisun invests extensively in the fields of regenerative and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun and Harvard University Stem Cell Research Institute, Johns Hopkins Medical School Life Science Center, Tsinghua University and other institutions have long-term cooperation plans to jointly invest in regenerative and stem cell therapy technology, with Medisun as a cooperative business The holding entity and holds global intellectual property rights. Medisun and the University of Maryland’s Institute of Human Virology (IHV) set up a technology clinical trial and development platform for viruses and cancer. Based on the Medisun Biomedical Laboratory in Hong Kong, Radiation will jointly build medical clinics in China and Asia. The experimental resource network promotes the world’s largest clinical research and development platform for virus research and cancer treatment technology. The Medisun Reproductive Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments.

For more information, please visit http://www.medisun.hk/

About Profectus BioSciences

Profectus BioSciences is a clinical stage vaccine development company focused on developing new vaccines for infectious disease and cancer prevention and treatment. The Profectus vaccine is based primarily on the company’s proprietary VesiculoVax™ and DNA vaccine technology platform. By simply using the VesiculoVax™ vaccine alone, B cells can be rapidly expanded to provide protection against emerging infectious diseases that threaten public health and biodefense mechanisms, such as Ebola, Marburg, Chikungunya, Zika virus, equine encephalitis virus, and respiratory syncytial virus. When VesiculoVax™ is used as a vaccine when the immune system is launched with the best pDNA vaccine, the Vesiculo Vax™-directed vaccine expands the triggered T cells into effector cells, which are ideal for attacking virus-infected cells and cancer. Current projects using the Prime / Boost Vaccine System (PBS Vax™) strategy include hepatitis B virus (HBV), human papillomavirus (HPV), herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus ( HIV). Partners and collaborators include UTMB’s Galveston National Laboratory, Yale University, University of Maryland Human Virology Institute, HIV/AIDS Vaccine Immunology Center, National Cancer Institute, National Institutes of Health AIDS Division, Bill And the Melinda Gates Foundation, the International AIDS Vaccine Initiative, the AIDS Vaccine Trial Network and the AIDS Clinical Trial Group. Profectus is funded by Cross Atlantic Capital Partners (“XACP”) in Radnor, Pennsylvania. The main investor in XACP is the Pennsylvania Public School Employees Retirement System (“PSERS”). For more information, please visit www.profectusbiosciences.com

Business Comments Off on Leading vaccine company born from Profectus Biotech and Medisun Medical Group new joint venture

The famous American vaccine company Profectus settled in Hong Kong

May
07

The famous American vaccine company Profectus settled in Hong Kong

First recommend HPV cervical cancer treatment vaccine

BALTIMORE, MARYLAND, USA and HONG KONG, April 20, 2018

Profectus Biotech and Medisun Medical Group today announced the opening of a new joint venture in Hong Kong. The primary mission of the new company, ProMed BioSciences, Ltd., is to establish a leading vaccine company focused on the development of preventive and therapeutic vaccines for infectious diseases and cancer. The joint venture will leverage Profectus’ vaccine development expertise, clinically proven vaccine platform technology and a developing vaccine product line, in line with Medisun’s expertise, established clinical network and market access capabilities, expected in the second half of 2018 to put into operation.

The company’s first product development program will focus on the development, production and commercial application of prophylactic and therapeutic vaccines for HPV (human papillomavirus)-related lesions and cervical cancer [based on PBSVax® technology developed by Profectus]. ProMed BioSciences also plans to develop and treat hepatitis C virus (HCV), hepatitis B virus (HBV), herpes simplex virus (HSV), respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV). Chikungunya and Zika, as well as personalized vaccines to treat cancer. The joint venture is expected to launch new vaccines in their respective markets, which will help promote the development of new vaccines, but ultimately the goal is to benefit patients around the world.

Mr. Jeffery Meshulam (first from left), President of Profectus Biotechnology, Mr. Terry Lierman (second from left), Chairman of Medivh Medical Group, and Mr. Danny Wong (fourth from right), founder and executive chairman of Medisun Medical Group, at Profectus ,USA.

– Long-term strategic cooperation to address the huge demand for prevention and treatment of infectious diseases and cancer in Asia

-Profectus’ expertise in vaccine development and platform technology, combined with Medisun’s localized expertise and experience, to establish a leading Hong Kong vaccine company focused on serving Asia

“This strategic cooperation will help establish Profectus’ business in Hong Kong and China. Through close cooperation with Medisun, we can assist Hong Kong and China to develop advanced vaccine technology to help prevent and treat Asian patients. Mr. Jeffrey Meshulam, President of Profectus, said, “We are pleased to be able to work with recognized local partners to achieve the highest standards of scientific research and development integration and medical services.”

“This collaboration will help Profectus and Medisun to jointly produce life-saving vaccines for infectious diseases and cancer, and address the huge medical needs that have not been met in Hong Kong, China and Asia.” Mr. Danny Wong, founder and executive chairman of Medisun Medical Group, said “ProMed BioSciences will leverage Profectus’ expertise in vaccine development and technology, combined with Medisun’s local expertise and close links with healthcare facilities in Hong Kong and China, and government medical regulatory agencies to develop vaccines to provide leadership for Asian patients disease prevention and treatment programs.”

ProMed BioSciences will focus on the following:

• Conduct technical research in Hong Kong or China

• Conduct clinical trials in Hong Kong or China

• Promote the expansion of Medisun Medical Center

• Develop vaccines to address disease prevention needs

• leverage to maximize the expertise of both partners

Mr. Jeffery Meshulam, President of Profectus Biotechnology (first from left), Mr. Terry Lierman, Chairman of Medisun Medical Group (first from right), Mr. Danny Wong, founder and executive chairman of Medisun Medical Group (middle), at the US headquarters of  Profectus.

About ProMed BioSciences

ProMed BioSciences Limited is a joint venture between Profectus BioSciences (USA) and Medisun Medical Group (Hong Kong) in Hong Kong to develop and conduct new vaccine clinical trials and commercial applications to address infectious diseases and cancer in Asia with the huge demand for prevention and treatment.

About Medisun

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as quality hospitals and treatment centers. Medisun invests extensively in the fields of regenerative and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun and Harvard University Stem Cell Research Institute, Johns Hopkins Medical School Life Science Center, Tsinghua University and other institutions have long-term cooperation plans to jointly invest in regenerative and stem cell therapy technology, with Medisun as a cooperative business The holding entity and holds global intellectual property rights. Medisun and the University of Maryland’s Institute of Human Virology (IHV) set up a technology clinical trial and development platform for viruses and cancer. Based on the Medisun Biomedical Laboratory in Hong Kong, Radiation will jointly build medical clinics in China and Asia. The experimental resource network promotes the world’s largest clinical research and development platform for virus research and cancer treatment technology. The Medisun Reproductive Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments.

For more information, please visit http://www.medisun.hk/

About Profectus BioSciences

Profectus BioSciences is a clinical stage vaccine development company focused on developing new vaccines for infectious disease and cancer prevention and treatment. The Profectus vaccine is based primarily on the company’s proprietary VesiculoVax™ and DNA vaccine technology platform. By simply using the VesiculoVax™ vaccine alone, B cells can be rapidly expanded to provide protection against emerging infectious diseases that threaten public health and biodefense mechanisms, such as Ebola, Marburg, Chikungunya, Zika virus, equine encephalitis virus, and respiratory syncytial virus. When VesiculoVax™ is used as a vaccine when the immune system is launched with the best pDNA vaccine, the Vesiculo Vax™-directed vaccine expands the triggered T cells into effector cells, which are ideal for attacking virus-infected cells and cancer. Current projects using the Prime / Boost Vaccine System (PBS Vax™) strategy include hepatitis B virus (HBV), human papillomavirus (HPV), herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus ( HIV). Partners and collaborators include UTMB’s Galveston National Laboratory, Yale University, University of Maryland Human Virology Institute, HIV/AIDS Vaccine Immunology Center, National Cancer Institute, National Institutes of Health AIDS Division, Bill And the Melinda Gates Foundation, the International AIDS Vaccine Initiative, the AIDS Vaccine Trial Network and the AIDS Clinical Trial Group. Profectus is funded by Cross Atlantic Capital Partners (“XACP”) in Radnor, Pennsylvania. The main investor in XACP is the Pennsylvania Public School Employees Retirement System (“PSERS”). For more information, please visit www.profectusbiosciences.com

Health Comments Off on The famous American vaccine company Profectus settled in Hong Kong

Latest Lab Equipment Equipment from ArrEssPro Scientific

May
02

ArrEssPro provides scientific laboratory equipment and supplies for research and educational purposes to schools, universities, industrial labs and more.

Below you’ll find some of our featured products from our wide selection of manufacturers. You’ll also see a couple featured categories. As well as be able to check on the latest News happening here at ArrEssPro, and the latest Blog articles.

ArrEssPro LLC is a Texas based company specializing in online sales. We offer all kind of scientific equipment and supplies. Here are few of our latest products:

Sper Scientific EMF Meter

Measures electro magnetic field emissions from electrical power lines and transmission equipment, computer, HVAC, audio/video, and other electrical appliances and equipment

While the evidence of the carcinogenic effect of such electromagnetic emissions is still inconclusive, prudent avoidance is recommended to avoid excess exposure over long periods of time. Reads milli-Gauss and micro-Tesla on a large 1″ high display. The display indicates when the object being measured is out of range as well as when the battery is low. Features both standard and maximum hold. Powered by a standard 9V battery lasting approximately 100 hours. Comes with battery, instructions, and a soft carrying case.

Dimensions: 5″ 2″ 1″ (127 51 32 mm)
Weight: 5.4 oz (153 g)

Unico Powerspin FX Centrifuge

PowerSpin FX spins at 3,400 rpm. The Power Spin FX series centrifuges are extremely quiet for a better working environment.

All PowerSpin FX models have a timer and on/off switch as well as other features that are normally only found on units costing much more.

FIXED SPEED 3400 RPM
8 PLACE FIXED ANGLE ROTOR
30 MIN. MECHANICAL TIMER
6X10ML CAPACITY
WITH 18 PLACE TUBE HOLDSTER RACK
POWER INPUT 110V

C800-00 8 Place Rotor
C800-01 8 Place Rotor
C800-75 Tachometer, Laser Digital with Reflective Tape, Batteries, In A Storage Case
C800-02 Regular tube shield, pack of 2
C800-03 Adapter for short tubes, pack of 10
C800-04 Pediatric or microtube adapter, pack of 2
C800-05 Tube Lift Adapters, Pk/12
C800-12 Balance Tube Holdster

https://arresspro.com/major-science-digital-peristaltic-pump

The easy-to-use pump design allows for several different silicon tubing sizes to be fitted. This gives the user a wider variety of flow rates.

The MU-D series is also reversible providing better convenience and flexibility to the user. The digital control provides high accurate rpm performance.

MU-D01 pump is a digital controlled mode with a solid 50W brushless motor, and MU-D02 is designed with a higher horsepower, 100W for higher volume demands required.

MU-D03 pump is the most powerful pump in this series which packs with powerful pump head, allows the flow rate to up to 3.3 litre/min with thicker tubing (1.6mm).

Select the appropriate model for your lab with economical yet powerful enough peristaltic pump.

Features:

For MU-D01 and MU-D02:

Digital microprocessor control for accurate control
Compact size for easy transportation
High quality Watson Marlow Easy load pump head
Flow rate range from 1.2 to 1140 ml/min for MU-D01 and 0.3 to 2280 ml/min for MU-D02 for wide applications
Reversible for purging

For MU-D03:

Digital microprocessor control for accurate control
High quality Watson Marlow pump head
Speed range from 20 to 300 rpm with 1 rpm increment
Flow rates from 0.8 ml/min to 3.3 litre/min using 1.6 mm wall thickness tubing
Robust pumphead construction with PPS (polyphenylene sulphide) track and rotor and stainless steel rollers and bearings
High efficiency maintenance free brushless DC motor
Tubing size ranges from 0.5mm to 8.0 mm (I.D) for wider application and usage

Please visit our online store and contact us for any questions:
https://arresspro.com/
ArrEssPro LLC
PO Box 51663
Denton, TX 76206-1663

Science , , , , Comments Off on Latest Lab Equipment Equipment from ArrEssPro Scientific